Top of this page
Skip navigation, go straight to the content

Clinical Studies Overview

Welcome to our

Clinical Studies section

 

Development of new drugs

UCB researchers seek to understand, prevent and treat diseases.
Clinical studies involving healthy volunteers and patients play a vital role in the development of new drugs.

Patients are enrolled in clinical studies that are consistent with the principles that have their origin in the Declaration of Helsinki and its amendments as well as the laws, regulations and provisions of those countries where humans are enrolled.

 

 
 



Find out more about a selection of studies

 

Electroencephalographic neonatal seizures - "PETITE" Study – N01349

https://petitestudy.com

A Phase 2/3, Multicenter, Open-Label, Single-Arm Study to evaluate the Pharmacokinetics, Efficacy and Safety of Brivaracetam in Neonates with Repeated Electroencephalographic Seizures

Recruiting

Status

Immune Mediated Necrotizing Myopathy  - IMNM01

Safety and Efficacy Study of Zilucoplan in Subjects With Immune-Mediated Necrotizing Myopathy

Recruiting

Status

Systemic lupus erythematosus - "PHOENYCS GO" study - SL0043

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

Recruiting

Status

Generalized Myasthenia Gravis - "RAISE" study - MG0009

www.gmgstudy.com

A multicenter, randomized, double-blind, placebo controlled study to confirm the efficacy, safety, and tolerability of zilucoplan in subjects with generalized Myasthenia Gravis.

Recruiting

Status

Chronic Inflammatory Diseases - "CHERISH" study - UP0085

www.thecherishstudy.com

A Postmarketing, Multicenter, Longitudinal, Prospective, Pharmacokinetic, Phase 1B Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol)

Recruiting

Status

Moderate to Severe Chronic Plaque Psoriasis - "CIMCare" study - PS0007

www.cimcarestudy.com

Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled (12-17 Years) Including a Single Open-Label Arm (6-11 Years) Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol (CZP) in Pediatric Study Participants With Moderate to Severe Chronic Plaque Psoriasis (PSO)

Recruiting

Status

Hidradenitis Suppurativa - "Be Heard" study - HS0004

https://beheardstudy.com

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

Recruiting

Status

Hidradenitis Suppurativa - "Be Heard" study - HS0003

https://beheardstudy.com

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

Recruiting

Status

Primary Immune Thrombocytopenia - "myOpportunITy 1" study - TP0003

www.myopportunitystudies.com

A Phase 3 Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)

Recruiting

Status

Primary Immune Thrombocytopenia - "myOpportunITy 2" study - TP0006

www.myopportunitystudies.com

A Phase 3 Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)

Recruiting

Status

Myasthenia Gravis - "MycarinGStudy" - MG0003

www.mycaringstudy.com

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis

Recruiting

Status

Nonradiographic axial spondyloarthritis - "BE MOBILE 1" study - AS0010

www.bemobilestudy.com

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled StudyA Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial Spondyloarthritis.

Recruiting

Status

Ankylosing spondylitis - "BE MOBILE 2" study - AS0011

www.bemobilestudy.com

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis.

Recruiting

Status

Psoriatic arthritis - "BE OPTIMAL" study - PA0010

www.beoptimalstudy.com

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Active Reference (Adalimumab) Study Evaluating the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis.

Recruiting

Status

Psoriatic arthritis - "BE COMPLETE" study - PA0011

www.becompletestudy.com

A Multicenter, Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis.

Recruiting

Status

Discover more about our clinical studies

Interested in enrolling in our study?

Just contact us



Austria

UCBCares.AT@ucb.com
+43 (0) 1 291 80 08
0800-296176 (freephone)

 


Belgium

UCBCares.BE@ucb.com
+32 2 559 92 00
0800 38 008 (freephone)
www.ucbcares.be



 

Bulgaria

UCBCares.BG@ucb.com
+359 2 962 9933



 

Czech Republic

UCBCares.CZ@ucb.com
+420 221 773 442
800 144 395 (freephone)

 

Denmark

UCBCares.DK@ucb.com
+45 32462480
80 253827 (freephone)


 

Finland

UCBCares.FI@ucb.com
+358 942733300
0800 9 13353 (freephone)


 

France

UCBCares.FR@ucb.com
+33 1 47 29 45 55
0 805 222 949 (freephone)


 

Germany

UCBCares.DE@ucb.com
+49 2173 48 48 48
www.ucbcares.de

 

Greece

UCBCares.GR@ucb.com
+30 21 0997 4200
0080 012 9910 (freephone)


 

Hungary

UCBCares.HU@ucb.com
+36 1 472 5060
06 80 021 486 (freephone)



 

Ireland

UCBCares.IE@ucb.com
+353 1 463 2371
1800 93 00 75 (freephone)
www.ucbcares.co.uk


 

Italy

UCBCares.IT@ucb.com
+39 02 3007 9300
8009-86932 (freephone)
www.ucbcares.it



 

Luxemburg

UCBCares.LU@ucb.com
+32 2 559 92 12
8002 3204 (freephone)



 

Norway

UCBCares.NO@ucb.com
+45 32462482
800-10101 (freephone)



 

Poland

UCBCares.PL@ucb.com
+48 22 596 97 97
00 800 121 68 25 (freephone)



 

Portugal

UCBCares.PT@ucb.com
+351 213 025 300
800-8-56033 (freephone)


 

Slovakia

UCBCares.SK@ucb.com
+421 2 592 020 23
0800 002 566 (freephone)



 

Spain

UCBCares.ES@ucb.com
+34 915 70 06 49
8000-99684 (freephone)
www.ucbcares.es


 

Sweden

UCBCares.SE@ucb.com
+45 32462481
0200 898 671 (freephone)


 

The Netherlands

UCBCares.NL@ucb.com
+31 76 573 1130
0800 3434335 (freephone)
www.ucbcares.nl

 

 

UK

UCBCares.UK@ucb.com
+44 1753 777 100
0800 279 3177 (freephone)
www.ucbcares.co.uk


Inspired by patients, driven by science
 
 

Disease resources

Learn more about epilepsy
Rheumatoid arthritis
Learn more about osteoporosis
Learn more about psoriasis
Parkinson's disease
Restless Legs Syndrome
Psoriatic arthritis
Axial Spondyloarthritis
Learn more about juvenile idiopathic arthritis
Learn more about lupus
Crohn's disease